TSPAN5, ERICH3 and selective serotonin reuptake inhibitors in major depressive disorder: pharmacometabolomics-informed pharmacogenomics

M. Gupta, D. Neavin, D. Liu, Joanna M Biernacka, D. Hall-Flavin, William V Bobo, Mark A Frye, M. Skime, G. D. Jenkins, A. Batzler, Krishna R Kalari, W. Matson, S. S. Bhasin, H. Zhu, T. Mushiroda, Y. Nakamura, M. Kubo, Liewei M Wang, R. Kaddurah-Daouk, Richard M Weinshilboum

Research output: Contribution to journalArticle

38 Citations (Scopus)

Abstract

Millions of patients suffer from major depressive disorder (MDD), but many do not respond to selective serotonin reuptake inhibitor (SSRI) therapy. We used a pharmacometabolomics-informed pharmacogenomics research strategy to identify genes associated with metabolites that were related to SSRI response. Specifically, 306 MDD patients were treated with citalopram or escitalopram and blood was drawn at baseline, 4 and 8 weeks for blood drug levels, genome-wide single nucleotide polymorphism (SNP) genotyping and metabolomic analyses. SSRI treatment decreased plasma serotonin concentrations (P

Original languageEnglish (US)
JournalMolecular Psychiatry
DOIs
StateAccepted/In press - Feb 23 2016

Fingerprint

Pharmacogenetics
Major Depressive Disorder
Serotonin Uptake Inhibitors
Citalopram
Metabolomics
Single Nucleotide Polymorphism
Serotonin
Genome
Therapeutics
Research
Pharmaceutical Preparations
Genes

ASJC Scopus subject areas

  • Molecular Biology
  • Psychiatry and Mental health
  • Cellular and Molecular Neuroscience

Cite this

TSPAN5, ERICH3 and selective serotonin reuptake inhibitors in major depressive disorder : pharmacometabolomics-informed pharmacogenomics. / Gupta, M.; Neavin, D.; Liu, D.; Biernacka, Joanna M; Hall-Flavin, D.; Bobo, William V; Frye, Mark A; Skime, M.; Jenkins, G. D.; Batzler, A.; Kalari, Krishna R; Matson, W.; Bhasin, S. S.; Zhu, H.; Mushiroda, T.; Nakamura, Y.; Kubo, M.; Wang, Liewei M; Kaddurah-Daouk, R.; Weinshilboum, Richard M.

In: Molecular Psychiatry, 23.02.2016.

Research output: Contribution to journalArticle

Gupta, M, Neavin, D, Liu, D, Biernacka, JM, Hall-Flavin, D, Bobo, WV, Frye, MA, Skime, M, Jenkins, GD, Batzler, A, Kalari, KR, Matson, W, Bhasin, SS, Zhu, H, Mushiroda, T, Nakamura, Y, Kubo, M, Wang, LM, Kaddurah-Daouk, R & Weinshilboum, RM 2016, 'TSPAN5, ERICH3 and selective serotonin reuptake inhibitors in major depressive disorder: pharmacometabolomics-informed pharmacogenomics', Molecular Psychiatry. https://doi.org/10.1038/mp.2016.6
Gupta, M. ; Neavin, D. ; Liu, D. ; Biernacka, Joanna M ; Hall-Flavin, D. ; Bobo, William V ; Frye, Mark A ; Skime, M. ; Jenkins, G. D. ; Batzler, A. ; Kalari, Krishna R ; Matson, W. ; Bhasin, S. S. ; Zhu, H. ; Mushiroda, T. ; Nakamura, Y. ; Kubo, M. ; Wang, Liewei M ; Kaddurah-Daouk, R. ; Weinshilboum, Richard M. / TSPAN5, ERICH3 and selective serotonin reuptake inhibitors in major depressive disorder : pharmacometabolomics-informed pharmacogenomics. In: Molecular Psychiatry. 2016.
@article{23482974c10d4b13987e433cbc32f22f,
title = "TSPAN5, ERICH3 and selective serotonin reuptake inhibitors in major depressive disorder: pharmacometabolomics-informed pharmacogenomics",
abstract = "Millions of patients suffer from major depressive disorder (MDD), but many do not respond to selective serotonin reuptake inhibitor (SSRI) therapy. We used a pharmacometabolomics-informed pharmacogenomics research strategy to identify genes associated with metabolites that were related to SSRI response. Specifically, 306 MDD patients were treated with citalopram or escitalopram and blood was drawn at baseline, 4 and 8 weeks for blood drug levels, genome-wide single nucleotide polymorphism (SNP) genotyping and metabolomic analyses. SSRI treatment decreased plasma serotonin concentrations (P",
author = "M. Gupta and D. Neavin and D. Liu and Biernacka, {Joanna M} and D. Hall-Flavin and Bobo, {William V} and Frye, {Mark A} and M. Skime and Jenkins, {G. D.} and A. Batzler and Kalari, {Krishna R} and W. Matson and Bhasin, {S. S.} and H. Zhu and T. Mushiroda and Y. Nakamura and M. Kubo and Wang, {Liewei M} and R. Kaddurah-Daouk and Weinshilboum, {Richard M}",
year = "2016",
month = "2",
day = "23",
doi = "10.1038/mp.2016.6",
language = "English (US)",
journal = "Molecular Psychiatry",
issn = "1359-4184",
publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - TSPAN5, ERICH3 and selective serotonin reuptake inhibitors in major depressive disorder

T2 - pharmacometabolomics-informed pharmacogenomics

AU - Gupta, M.

AU - Neavin, D.

AU - Liu, D.

AU - Biernacka, Joanna M

AU - Hall-Flavin, D.

AU - Bobo, William V

AU - Frye, Mark A

AU - Skime, M.

AU - Jenkins, G. D.

AU - Batzler, A.

AU - Kalari, Krishna R

AU - Matson, W.

AU - Bhasin, S. S.

AU - Zhu, H.

AU - Mushiroda, T.

AU - Nakamura, Y.

AU - Kubo, M.

AU - Wang, Liewei M

AU - Kaddurah-Daouk, R.

AU - Weinshilboum, Richard M

PY - 2016/2/23

Y1 - 2016/2/23

N2 - Millions of patients suffer from major depressive disorder (MDD), but many do not respond to selective serotonin reuptake inhibitor (SSRI) therapy. We used a pharmacometabolomics-informed pharmacogenomics research strategy to identify genes associated with metabolites that were related to SSRI response. Specifically, 306 MDD patients were treated with citalopram or escitalopram and blood was drawn at baseline, 4 and 8 weeks for blood drug levels, genome-wide single nucleotide polymorphism (SNP) genotyping and metabolomic analyses. SSRI treatment decreased plasma serotonin concentrations (P

AB - Millions of patients suffer from major depressive disorder (MDD), but many do not respond to selective serotonin reuptake inhibitor (SSRI) therapy. We used a pharmacometabolomics-informed pharmacogenomics research strategy to identify genes associated with metabolites that were related to SSRI response. Specifically, 306 MDD patients were treated with citalopram or escitalopram and blood was drawn at baseline, 4 and 8 weeks for blood drug levels, genome-wide single nucleotide polymorphism (SNP) genotyping and metabolomic analyses. SSRI treatment decreased plasma serotonin concentrations (P

UR - http://www.scopus.com/inward/record.url?scp=84959121708&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84959121708&partnerID=8YFLogxK

U2 - 10.1038/mp.2016.6

DO - 10.1038/mp.2016.6

M3 - Article

C2 - 26903268

AN - SCOPUS:84959121708

JO - Molecular Psychiatry

JF - Molecular Psychiatry

SN - 1359-4184

ER -